Literature DB >> 17895751

Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung.

Giuliana Sartori1, Stefania Bettelli, Laura Schirosi, Nazzarena Bigiani, Antonio Maiorana, Alberto Cavazza, Giulio Rossi.   

Abstract

Sclerosing hemangioma (SH) is an uncommon pulmonary tumor thought to derive from primitive respiratory epithelium consisting of 2 cell populations (cuboidal surface and polygonal stromal cells) and sharing some clinical characteristics (frequent occurrence in nonsmoking women of Asian ethnicity) with bronchioloalveolar carcinoma with which it has been suggested a possible common origin. We investigated 11 cases of SH by immunohistochemistry, fluorescence in situ hybridization, and polymerase chain reaction-based microsatellite and mutational analyses with particular emphasis on possible alterations of microsatellite loci located at tumor suppressor genes (FHIT, p16, Rb, and p53) involved in lung adenocarcinoma genesis and EGFR, HER2, and K-RAS genes. Although EGFR expression was observed in all tested cases, none showed HER2 immunostaining. Fluorescence in situ hybridization and mutational analysis of EGFR and HER2 and also K-RAS sequencing did not reveal molecular alterations, whereas allelic losses at p16 and Rb loci (4 and 2 out of 9 tested cases, respectively) with an identical microsatellite allelic loss pattern in both cuboidal and polygonal cells were observed. The finding of microsatellite alterations in chromosomal regions related to genes deeply involved in early stage lung adenocarcinoma could suggest a possible link between SH and bronchioloalveolar carcinoma, but tumor pathway promoted by EGFR, HER2, and K-RAS does not represent a common molecular mechanism of tumorigenesis. Microsatellite alterations identified in cuboidal and polygonal cells further confirm the clonal and neoplastic nature of both components of SH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17895751     DOI: 10.1097/PAS.0b013e318032c8cc

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.

Authors:  Seung-Hyun Jung; Min Sung Kim; Sung-Hak Lee; Hyun-Chun Park; Hyun Joo Choi; Leeso Maeng; Ki Ouk Min; Jeana Kim; Tae In Park; Ok Ran Shin; Tae-Jung Kim; Haidong Xu; Kyo Young Lee; Tae-Min Kim; Sang Yong Song; Charles Lee; Yeun-Jun Chung; Sug Hyung Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

2.  Pulmonary sclerosing pneumocytoma: Cytomorphology and immunoprofile.

Authors:  Zahra Maleki; Stephanie Muller; Lester Layfield; Momin T Siddiqui; Natasha Rekhtman; Liron Pantanowitz
Journal:  Cancer Cytopathol       Date:  2020-02-05       Impact factor: 4.264

3.  A mixture of carcinoid tumors, extensive neuroendocrine proliferation, and multiple pulmonary sclerosing hemangiomas.

Authors:  Yihong Wang; Qicai He; Wei Shi; Jun Wang; Hongxiu Ji
Journal:  World J Surg Oncol       Date:  2014-07-15       Impact factor: 2.754

4.  [Diagnosis and treatment for pulmonary sclerosing hemangioma].

Authors:  Shaohua Ma; Yu Sun; Changzheng Du; Zhen Liang; Hongchao Xiong; Keneng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-08

Review 5.  Pulmonary sclerosing pneumocytoma: clinical features and prognosis.

Authors:  Quan Zheng; Jian Zhou; Guangchen Li; Shulei Man; Zhangyu Lin; Tengyong Wang; Boran Chen; Feng Lin
Journal:  World J Surg Oncol       Date:  2022-04-30       Impact factor: 3.253

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.